{
  "id": 10674898,
  "title": "Novo to spend $300M upfront to license Hengrui's weekly oral weight loss drug",
  "url": "https://urgent.news/2026/09/29/novo-to-spend-300m-upfront-to-license-hengruis-weekly-oral-weight",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-29T11:04:17.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/novo-to-spend-300m-upfront-to-license-hengruis-weekly-oral-weight-loss-drug/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Novo has signed its fourth weight loss-focused pact of the year, this time tapping a preclinical GLP-1/GIP receptor agonist from China’s Hengrui that could be dosed as little as once a week. The Danish drugmaker ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 3,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Hengrui Pharma shares rise as Novo Nordisk signs $2.6 billion drug deal",
        "url": "https://urgent.news/2026/09/29/hengrui-pharma-shares-rise-as-novo-nordisk-signs-2-6-billion-drug-deal",
        "published": "2026-09-29T05:16:50.000Z"
      },
      {
        "outlet": "Seeking Alpha News",
        "title": "Novo Nordisk strikes $2.6B obesity drug deal with China's Hengrui",
        "url": "https://urgent.news/2026/09/29/novo-nordisk-strikes-2-6b-obesity-drug-deal-with-chinas-hengrui",
        "published": "2026-09-29T05:56:34.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}